• Expanded Access Programs
  • Imports (Unlicensed Medicines)
  • International Sales
  • Clinical Trial Supply
  • Sales to NGOs & Charities
  • Sexual Health Supplies
  • Bespoke Distribution
  • Durbin USA
  • About Us
  • News
  • Contact Us
  • News

    ​Medical Need Europe appoints Durbin as latest distribution partner

    03 August 2015

    Medical Need Europe has appointed Durbin,one of the world’s leading specialist medical suppliers and distributors of pharmaceuticals, to manage the warehousing and supply chain for a range of its products. Initially this agreement will involve a single product, MD1003, which is currently under clinical development for the management of progressive multiple sclerosis (MS).

    Durbin will coordinate the distribution of MD1003 through its Managed Access Programme (MAP), which will enable patients with a physician-assessed clinical need to receive the product before it is commercially available.

    Peder Walberg, CEO of Medical Need, says:

    “Initial feedback from neurologists and the MS community indicated that there will be requests for MD1003 on a Named Patient or Early Access basis. We believe our collaboration with Durbin will strengthen our logistical setup and improve our ability to answer the requests for MD1003 in these markets."

    “While we are very pleased with our existing partnership with BS Orphan, to provide medical support services for our products in the UK, Ireland and Netherlands, our upcoming pipeline of products for unmet medical needs required further services within the current setup. Medical Need required an additional logistics partner with regulatory expertise and experience, which could be trusted to effectively manage the supply as requested and permitted. Durbin met these criteria, and we are very happy to be working with them.”

    Durbin has over 20 years’ experience in Named Patient and Early Access programmes, working with leading pharmaceutical and biotechnology companies to distribute products on a global scale.

    Leslie Morgan, CEO of Durbin, comments:

    “Durbin has been managing several programs within the MS arena, and we look forward to continuing to contribute to improved patient care through access to MD1003 in these markets. A project of this scale requires a specialist global distributor with regulatory experience, and our previous work, along with patient focus positions us well for our partnership with Medical Need.”

    “Medical Need is a specialist and dynamic company which is dedicated to improving the lives of patients with unmet medical needs and we welcome the opportunity to work in partnership with both them and BS Orphan.”

    Further treatments for the management of patients with unmet clinical needs in gastro-intestinal and other conditions are expected to launch under this arrangement in the coming months.

    About Medical Need

    Medical Need is a privately held pharmaceutical company headquartered in Sweden, focusing on the registration, distribution, marketing and sale of orphan drugs and niche speciality pharmaceuticals across Europe, for the treatment of rare diseases where there is a high unmet medical need. The company is currently active within several rare and niche disorders, such as; Urea Cycle Disorders, Niemann-Pick type C, Congenital-Sucrase-Isomaltase Deficiency, progressive multiple sclerosis (MS), haematological stem cell transplantation, brain tumours, multi-resistant tuberculosis and Ménières disease.

    For further information please contact Victoria Ellis Victoria@kisscom.co.uk or Sophie Davis Sophie@kisscom.co.uk T: 01223 911 123

    Press Releases